Dosage Forms

Articles

The UK government has secured early access to 90 million COVID-19 vaccine doses from the BioNTech/Pfizer alliance and Valneva.

UK Government Secures Early Access to Millions of COVID-19 Vaccine Doses

Preliminary data from a German Phase I/II trial shows Pfizer/BioNTech COVID-19 vaccine candidate produces immune response.

mRNA Vaccine Produces Immune and T-cell Response

Strong immune response by patients receiving two doses of vaccine suggests a possible treatment strategy.

AstraZeneca Vaccine Shows Antibody and T-cell responses

Global regulatory authorities have published a report describing the aligned positions on COVID-19 vaccine development, which were agreed upon by meeting participants of the second workshop on COVID-19 vaccine development.

Regulatory Authorities have Published a Report on COVID Vaccine Development

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

FDA officials are moving to clarify standards and requirements for vetting and approving viable preventives. 

FDA Maps Expectations for COVID Vaccine Proposals

GlaxoSmithKline (GSK) and Medicago have announced a collaboration for the development and evaluation of a COVID-19 vaccine candidate. 

GSK, Medicago Collaborate on Covid-19 Vaccine Candidate

The agreement will fund the late-stage clinical development, a Phase III clinical trial, large-scale manufacturing, and the delivery of 100 million doses of Novavax’s COVID-19 vaccine candidate, NVX‑CoV2373. 

Novavax Awarded $1.6 Billion from Operation Warp Speed

Emergent is entering into a five-year agreement with Janssen Pharmaceuticals for the large-scale drug substance manufacturing of Johnson & Johnson’s investigational COVID-19 vaccine, Ad26.COV2-S.

Emergent and Johnson & Johnson Enter into $480 Million Manufacturing Agreement for COVID-19 Vaccine

Intravacc will license CimCure’s iBoost technology, and the companies will jointly develop a COVID-19 vaccine candidate.

Intravacc, CimCure Partner to Develop COVID-19 Vaccine

Aji Bio-Pharma launched Ajility, a flexible platform for manufacturing vaccines and therapies.

Vaccines